Another Licence, Another Milestone. FINA Supports Internode Pharma to Secure MS and Schedule 1 CD Licences

Internode Pharma has successfully secured both a Manufacturer’s Specials (MS) licence and a Schedule 1 Controlled Drugs licence from the MHRA and Home Office; another key milestone in the UK’s regulated medicinal cannabis sector.

This is the third site we’ve guided through licensing at this level, building on our role in operationalising the UK’s first MS/CD licence for cannabis-based medicines in 2019.

With these approvals, Internode Pharma is ready for full commercial supply, enabling new lines of cannabis-based medicines and improved outcomes for UK patients.

Our support focused on:

• Aligning GMP systems with site operations and cannabis-specific requirements

• Meeting Home Office readiness criteria for Schedule 1 substances

• Developing a regulatory-informed, risk-reduced commercial strategy.

  
  

This achievement further strengthens the UK’s medical cannabis landscape and highlights FINA’s ongoing role in enabling compliant, patient-focused innovation.